PMC:7289100 / 37226-37407
Annnotations
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T279 | 89-90 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T280 | 150-155 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T281 | 159-160 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T141 | 54-65 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T228 | 0-181 | Sentence | denotes | In the course of this therapy, 4 weeks after the last tocilizumab infusion, she reported a contact with Covid-19 and was found to be positive for the virus by a nasopharyngeal swab. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T492 | 54-65 | DG_35 | denotes | tocilizumab |
| T493 | 104-112 | SP_7 | denotes | Covid-19 |
| T494 | 150-155 | NCBITaxon:10239 | denotes | virus |
| T495 | 161-175 | UBERON:0001728 | denotes | nasopharyngeal |
| T10818 | 54-65 | DG_35 | denotes | tocilizumab |
| T52732 | 104-112 | SP_7 | denotes | Covid-19 |
| T62313 | 150-155 | NCBITaxon:10239 | denotes | virus |
| T34080 | 161-175 | UBERON:0001728 | denotes | nasopharyngeal |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1201 | 54-65 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 1275 | 104-112 | Disease | denotes | Covid-19 | MESH:C000657245 |